Jianqin Lu

Research Interests

Jianqin Lu, B.Pharm., PhD, Assistant Professor of Pharmaceutical Sciences in Pharmaceutics and Pharmacokinetics, College of Pharmacy. The overarching goal of the Lu lab is to apply synthetic chemistry, nanoparticle engineering, and tumor immunology to develop efficacious nanotherapeutics to address the pressing unmet needs in current cancer therapy. Dr. Lu’s graduate research focused on developing dual functional nanomicelles for synergistic tumor targeted delivery of chemotherapeutics for improved anticancer efficacy and reduced side effects for treating breast, prostate, and cervical cancers, which honed his expertise in conjugation/peptide chemistry, nanoformulations (micelles, liposome, emulsions, etc.), as well as in vitro and in vivo therapeutic studies. Dr. Lu was the recipient of the Norman R. and Priscilla A. Farnsworth Award among others at Pitt. During the postdoctoral training at UCLA, Dr. Lu dived into nano-enabled cancer immunotherapy research area, where he developed a robust two-wave immunotherapeutic nanoplatform through concurrently triggering the tumor specific immunogenicity by instigating the immunogenic cell death (ICD) at tumor site, and inhibiting the immunosuppressive metabolic immune checkpoint IDO pathway for treating pancreas and breast cancers, from which he gained extensive knowledge in tumor immunology and was awarded an NIH NRSA T32 training grant in Tumor Immunology. The Lu Lab’s expertise in Pharmaceutics, Drug Delivery, Nanomedicine and Tumor Immunology paves the way to develop transformative and clinically translatable nano-enabled immunotherapeutics for combatting cancers. Dr. Lu has published 24 research articles, 1 book chapter, and 2 patent applications (One has been licensed) as well as been the invited speakers including the prestigious 41st Controlled Release Society Annual Meeting & Exposition. Dr. Lu received a PhD degree in Pharmaceutics from University of Pittsburgh (2014), and completed a NIH Postdoctoral Fellowship at Department of Chemistry, The University of Chicago (2015), and a NIH Postdoctoral Fellowship in Nanomedicine/Tumor Immunology at California NanoSystems Institute at UCLA (2019), respectively.